Yield10 Bioscience Announces Second Quarter 2017 Financial Results
WOBURN, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) today reported financial results for the three months ended June 30, 2017.
“We made solid progress in the second quarter driving toward the generation of proof points in our research and development programs,” commented Oliver Peoples, Ph.D., President and Chief Executive Officer. “We announced the start of field tests at sites in Canada in early June for the evaluation of our novel yield trait gene C3003 in Camelina and canola. Harvest of the crops is expected to start in the coming weeks. In addition, our C3003 yield trait has been introduced into soybean through a collaborator and greenhouse studies are currently underway. Progress with these studies keeps us on track to begin reporting out additional yield data on C3003 in oilseed crops starting in the fourth quarter of 2017.”
“We made solid progress in the second quarter driving toward the generation of proof points in our research and development programs,” commented Oliver Peoples, Ph.D., President and Chief Executive Officer. “We announced the start of field tests at sites in Canada in early June for the evaluation of our novel yield trait gene C3003 in Camelina and canola. Harvest of the crops is expected to start in the coming weeks. In addition, our C3003 yield trait has been introduced into soybean through a collaborator and greenhouse studies are currently underway. Progress with these studies keeps us on track to begin reporting out additional yield data on C3003 in oilseed crops starting in the fourth quarter of 2017.”